Dihydrotestosterone, usually called DHT, is the hormone most directly responsible for prostate growth throughout your life and the one most strongly linked to benign prostatic hyperplasia (BPH), the gradual enlargement that affects most men as they age. Your body makes DHT by converting testosterone inside prostate cells, and DHT binds to hormone receptors there with roughly four times the strength of testosterone itself, making it a far more powerful growth signal.1Endocrine Reviews. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels That potency is both necessary and, eventually, a liability. Understanding how DHT works in the prostate clarifies why drugs that suppress it can shrink an enlarged gland, and why the relationship between hormones and prostate trouble is less straightforward than many people assume.
How Testosterone Becomes DHT Inside the Prostate
Testosterone circulating in your blood is not the hormone doing most of the heavy lifting inside prostate tissue. An enzyme called 5-alpha reductase converts testosterone into DHT within the prostate’s stromal and basal cells. The prostate mainly expresses the type 2 version of this enzyme, though both type 1 and type 2 exist elsewhere in the body.2Urology. 5α-reductase activity in the prostate Once formed, DHT latches onto androgen receptors and stays bound much longer than testosterone does. It also pushes those receptors into a state that activates genes controlling cell growth and survival. On top of that, DHT encourages the prostate to produce more androgen receptors while slowing their breakdown, effectively amplifying its own signal.1Endocrine Reviews. Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels
One of the key ways DHT stimulates prostate growth is by acting on stromal cells, the supportive tissue surrounding the glandular parts of the prostate. When stromal cells are exposed to DHT, they ramp up production of growth factors, including keratinocyte growth factor (KGF), which in turn signals nearby epithelial cells to multiply.3PubMed. Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen This cross-talk between stromal and epithelial cells is a central feature of how the prostate grows, both during normal development and when things go wrong later.
DHT’s Role Across a Man’s Lifetime
DHT is not simply a troublemaker. During fetal development, it directs the formation of the prostate from undifferentiated tissue. During puberty, it drives the gland to its adult size. Without functioning androgen signaling, the prostate does not develop normally, and men who were castrated before puberty never develop BPH.4Asian Journal of Urology. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review The clinical observation that prostate enlargement requires lifelong androgen exposure is one of the oldest and strongest pieces of evidence connecting DHT to BPH.
As men age, the balance shifts. DHT continues to stimulate cell growth in the prostate, but the normal controls that limit how many cells accumulate begin to weaken. Populations of intermediate cells that are especially sensitive to DHT’s growth-amplifying effects may expand unchecked, and the usual regulation of both stromal and epithelial cell mass breaks down.5European Urology Supplements. The Androgen Cascade in Ageing Men: Blessing or Curse? The result is a slow, steady increase in prostate volume that can eventually squeeze the urethra and produce the familiar symptoms of BPH: a weak urine stream, frequent nighttime trips to the bathroom, and a sense that the bladder never fully empties.
Why Blood Testosterone Levels Can Be Misleading
A common misconception is that high testosterone in the blood means high DHT in the prostate and, therefore, a bigger prostate. The reality is more complicated. Studies measuring hormone levels directly in prostate tissue have found that serum testosterone does not reliably predict what is happening inside the gland.6PubMed. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer Researchers comparing tissue and blood samples from men with BPH and prostate cancer found no correlation between the two, concluding that intraprostatic hormone levels matter far more for assessing a man’s androgen status than a blood draw does.7Steroids. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer
Epidemiological data linking serum androgen levels to BPH risk are inconsistent. The general consensus is that androgens play a “permissive” role: you need some threshold of androgen activity for BPH to develop, but having more testosterone in your blood does not automatically mean your prostate will enlarge faster or to a greater degree.8Nature Reviews Urology. Estrogen and androgen signaling in the pathogenesis of BPH This matters practically because men considering testosterone replacement therapy sometimes worry they are fueling prostate growth. A randomized controlled trial measuring prostate tissue directly in men receiving testosterone replacement found that intraprostatic DHT levels barely changed, going from about 6.79 ng/g at baseline to 6.82 ng/g after treatment.9JAMA. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism: A Randomized Controlled Trial The prostate appears to regulate its own local hormone environment to a degree, which is why blood levels tell an incomplete story.
Inflammation and Metabolic Factors Add to the Picture
DHT does not act alone. Chronic low-grade inflammation and metabolic conditions like obesity and insulin resistance appear to work alongside DHT to promote prostate enlargement. Laboratory research has shown that DHT can increase the release of pro-inflammatory signals from immune cells (specifically a type of white blood cell called M1 macrophages), which then stimulate prostate stromal cells to proliferate.10PubMed Central. Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells Interestingly, the relationship between DHT and inflammation is not one-dimensional. In isolated BPH cells triggered by inflammatory stimuli, pretreatment with DHT actually suppressed the inflammatory response, reducing secretion of several inflammatory and growth factors.11Journal of Endocrinology. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells So DHT can be both pro-inflammatory and anti-inflammatory depending on the context, which complicates the notion that simply lowering it will fix everything.
Metabolic syndrome adds another layer. In men with features of metabolic syndrome, markers of inflammation like TNF-alpha and the hormone resistin were independently associated with prostate volume and BPH symptoms, even after accounting for age and testosterone levels.12PubMed. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume This is one reason why lifestyle factors like maintaining a healthy weight and controlling blood sugar may help with prostate health alongside (or sometimes instead of) hormonal interventions.
How DHT-Lowering Drugs Work
The most direct pharmaceutical approach to managing BPH targets the conversion step from testosterone to DHT. Drugs called 5-alpha reductase inhibitors (5-ARIs) block the enzyme responsible for that conversion. Two are widely prescribed: finasteride, which mainly inhibits the type 2 enzyme, and dutasteride, which blocks both type 1 and type 2.
The difference in how thoroughly they suppress DHT is substantial. Finasteride lowers serum DHT by about 70% and reduces DHT within the prostate by roughly 80 to 90%.13Korean Journal of Urology. The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride Dutasteride suppresses serum DHT by around 95% at the standard dose, with less variability between patients than finasteride achieves.14The Journal of Clinical Endocrinology & Metabolism. Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor Whether that difference in suppression translates into meaningfully better clinical outcomes for every patient is debated, but the pharmacological logic is clear: blocking more of the enzyme should leave less DHT in the tissue.
What Happens When You Lower DHT Over Time
5-ARIs are not quick-fix medications. They work gradually, and the benefits build over years. In a landmark four-year trial, finasteride shrank prostate volume by about 18% while the placebo group’s prostates grew by 14%. More meaningfully for patients, the finasteride group had a 57% lower risk of acute urinary retention (the painful inability to urinate at all) and a 55% lower risk of needing BPH-related surgery.15PubMed Central. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia These are the outcomes that matter most, because they represent avoiding a medical emergency or a trip to the operating room.
Longer follow-up data show that improvements continue accumulating. With dutasteride, symptom scores improved more after four years of treatment than after two, and urine flow rates continued to increase over the same period.16Clinical Therapeutics. A review of the clinical efficacy and safety of 5α-reductase inhibitors for the enlarged prostate Six-year data for finasteride showed that the reduced risk of urinary retention and surgery was maintained over the long term. Treatment guidelines recommend 5-ARIs for men with moderate to severe urinary symptoms and demonstrably enlarged prostates, though they are less effective for men with smaller glands because those men have less DHT-driven tissue to shrink.17PubMed Central. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH
DHT, Blood Vessels, and Prostate Bleeding
An underappreciated aspect of DHT’s influence on the prostate involves blood supply. DHT promotes the growth of tiny blood vessels (microvessels) within prostate tissue, particularly in the area just beneath the urethra. Men with BPH often have denser networks of these microvessels, which helps explain why blood in the urine is a common complaint. When finasteride was studied in this context, treated patients had significantly lower microvessel density in the suburethral prostate compared with untreated controls.18PubMed. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia This vascular effect kicks in fast: a randomized trial found that finasteride measurably reduced prostatic vascularity within just two weeks.19PubMed. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks
This finding has practical implications for surgery. When men undergo transurethral resection of the prostate (TURP), blood loss during the procedure can be significant. Giving a 5-ARI for as little as four weeks before surgery has been shown to reduce both operative blood loss and prostatic microvessel density, potentially lowering the need for blood transfusions.20PubMed. Transurethral resection of prostate and bleeding: A prospective randomized, double blind, placebo controlled trial to see efficacy of short term use of Finasteride and Dutasteride on operative blood loss and prostatic micro-vessel density So even for men headed toward surgery rather than long-term medical management, DHT suppression has a role to play.
Sexual Side Effects Are Real but Vary Widely
The trade-off with 5-ARIs that gets the most attention is sexual function. DHT is not just active in the prostate; it supports libido, erectile function, and other aspects of sexual health throughout the body. Suppressing it systemically can cause side effects. In clinical trials, sexual side effects including erectile dysfunction, reduced libido, and decreased ejaculate volume have been reported in roughly 3 to 16% of men taking these drugs.21PubMed Central. Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review
A smaller group of men report that sexual side effects persist even after stopping the drug, a phenomenon sometimes called post-finasteride syndrome. In one study of men who specifically reported persistent problems, 94% described low libido, 92% reported erectile dysfunction, and 69% had difficulty with orgasm.22The Journal of Sexual Medicine. Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss That study recruited men who had already identified themselves as having persistent issues, so its rates do not represent the general population taking 5-ARIs. But the existence of long-lasting effects in some individuals is taken seriously enough that the U.S. National Institutes of Health added post-finasteride syndrome to its Genetic and Rare Disease Information Center.21PubMed Central. Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review The science on why some men are affected and others are not remains incomplete. Talking to your doctor about your individual risk profile before starting a 5-ARI is worthwhile.
DHT Suppression and Prostate Cancer Risk
Whether lowering DHT affects prostate cancer risk has been studied directly. In a large randomized trial of over 4,300 men with BPH but no known prostate cancer, those given dutasteride for two years had a significantly lower cumulative incidence of prostate cancer compared with placebo: about 1.2% versus 2.5% at 27 months.23Urology. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia Similar findings came from the larger Prostate Cancer Prevention Trial with finasteride, though these trials also raised questions about whether the cancers detected in the drug group, while fewer in number, were slightly more likely to be higher-grade. That finding has been debated extensively, with many experts attributing it to detection bias: 5-ARIs shrink the prostate, which makes biopsies more likely to hit an existing tumor, and they lower PSA, which changes how screening is interpreted.
Speaking of PSA, 5-ARIs reliably lower prostate-specific antigen levels, which complicates cancer screening. Doctors typically use a “doubling rule,” multiplying measured PSA by two in men taking a 5-ARI, to get a rough estimate of what the value would be without the drug. Research suggests that using a rise of 0.3 ng/mL from the lowest achieved PSA as a trigger for biopsy maintains reasonable sensitivity for detecting prostate cancer in men on dutasteride.24PubMed. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations If you are on a 5-ARI, make sure your doctor knows, because an unadjusted PSA reading could falsely reassure you.
Saw Palmetto and Natural DHT Reduction
Saw palmetto is the most widely used herbal product for prostate symptoms, and part of its reputation rests on the idea that it works like a mild, natural 5-ARI. A randomized trial measuring DHT directly in prostate biopsy tissue found that saw palmetto reduced tissue DHT levels by about 32%, a modest but statistically significant drop.25Urology. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens That is a real pharmacological effect, but it is much smaller than what either finasteride or dutasteride achieves. Large clinical trials of saw palmetto for BPH symptoms have produced mixed results, with several well-designed studies finding no benefit over placebo for symptom scores. The herb likely does modestly lower intraprostatic DHT, but whether that translates into clinically meaningful symptom relief for most men remains unclear.
Genetic Variation and Individual Susceptibility
Not every man exposed to the same DHT levels develops the same degree of prostate enlargement, which points to genetics. One area of research involves a stretch of repeating DNA within the androgen receptor gene, called the CAG repeat. Shorter CAG repeat lengths are associated with a more active androgen receptor, meaning the receptor responds more strongly to DHT. Because BPH is androgen-dependent, researchers have hypothesized that men with shorter CAG repeats may be at higher risk of developing it.26Urology. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia The same genetic variation has been linked to prostate cancer risk. This kind of inherited difference in receptor sensitivity helps explain why two men of the same age, with similar hormone levels, can have very different prostate outcomes.
The discovery of congenital 5-alpha reductase deficiency in certain families was actually the breakthrough that revealed DHT’s distinct role in the first place. Males born with nonfunctional 5-alpha reductase have normal testosterone but virtually no DHT. They develop ambiguous genitalia at birth, and critically, their prostates remain small throughout life. They also do not develop male-pattern baldness or significant acne. This natural experiment demonstrated that testosterone and DHT are two functionally separate hormones, with DHT specifically responsible for prostate growth, facial hair, and scalp hair loss.27PubMed Central. 5alpha-reductase: history and clinical importance The entire class of 5-ARI drugs was developed based on that observation.
DHT’s Connection to Hair Loss and Acne
Because 5-ARIs lower DHT systemically, they affect every tissue that depends on it, not just the prostate. This is why finasteride at a lower dose is also prescribed for male-pattern hair loss: the same DHT that enlarges the prostate miniaturizes hair follicles on the scalp. Men taking a 5-ARI for BPH sometimes notice their hair thickening as a side benefit. Conversely, the sexual side effects discussed earlier are a consequence of the same whole-body DHT reduction. The drug cannot be targeted to one organ alone.
Acne and oily skin are also DHT-mediated. The type 1 isoenzyme of 5-alpha reductase, which is more active in skin and sebaceous glands, plays a larger role in these conditions.28PubMed Central. The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Dutasteride’s inhibition of both enzyme types is part of why it suppresses DHT more completely than finasteride, but it also means a broader physiological footprint. For men being treated primarily for prostate enlargement, these extra-prostatic effects are worth knowing about, because they can influence which drug a doctor recommends and how you weigh the benefits against the downsides.